(By Brian Zimmerman for Becker’s Hospital Review)
The Federal Trade Commission and the FDA on Wednesday issued joint warning letters to 11 marketers and distributors of 12 unapproved opioid cessation products.
Here are three things to know. Continue reading article here…
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.